Randomized Phase 1b/3 Study of Erlotinib + Ramucirumab in Untreated EGFR Mutation-Positive Stage IV NSCLC: Phase 1b Outcomes

Category Primary study
JournalJournal of Thoracic Oncology
Year 2017
This article has no abstract
Epistemonikos ID: 9de8bd4d82a489029c53fd3fe8e85bdae334e948
First added on: Feb 08, 2025